MedTrace Logo

Compatible Effect of Remimazolam Besylate Combined With Afentanil for ATI

NCT06026566 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2023-09-07

No results posted yet for this study

Summary

1. To study the pharmacokinetics between remimazolam besylate and alfentanil;
2. To determine the optimal dosage of the two drugs in awake endotracheal intubation;
3. To provide clinical guidance for awake endotracheal intubation.

Conditions

  • Remimazolam
  • Awake Endotracheal Intubation

Interventions

DRUG

Dos of Afentanil 20

the dosage of Afentanil is 20 ng/ml for TCI

DRUG

Dos of Afentanil 30

the dosage of Afentanil is 30 ng/ml for TCI

DRUG

Dos of Afentanil 40

the dosage of Afentanil is 40 ng/ml for TCI

DRUG

Dos of Afentanil 50

the dosage of Afentanil is 50 ng/ml for TCI

DRUG

Dos of Afentanil 60

the dosage of Afentanil is 60 ng/ml for TCI

DRUG

Dos of Afentanil 70

the dosage of Afentanil is 70 ng/ml for TCI

DRUG

Dos of Afentanil 80

the dosage of Afentanil is 80 ng/ml for TCI

DRUG

Dos of Afentanil 90

the dosage of Afentanil is 90 ng/ml for TCI

DRUG

Dos of Afentanil 100

the dosage of Afentanil is 100 ng/ml for TCI

Sponsors & Collaborators

  • Tongji Hospital

    lead OTHER

Principal Investigators

  • Qiaoqiao Xu · Tongji Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-01
Primary Completion
2025-08-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06026566 on ClinicalTrials.gov